Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Cresomycin
Catalog No.: PC-21855Not For Human Use, Lab Use Only.
Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides.
Cresomycin (CRM) is broadly superior to Iboxamycin (IBX) in inhibiting the growth of staphylococci (MIC90= 2 versus 8 ug/ml), streptococci MIC90 ≤ 0.06 versus 0.25 μg/ml), enterococci (MIC90 = 0.25 versus 2 μg/m), and Clostridioides difficile (MIC90= 0.125 versus 16 ug/ml).
Cresomycin (CRM) (25 mg/kg, q.i.d., i.p.) reduces the bacterial burden of cfr-expressing S. aureus, ermA-expressing S. aureus (AR-0693), carbapenem-resistant E. coli (AR-0137), and carbapenem-resistant P. aeruginosa (AR-0236) by -4.6, -2.2, -2.6, and -2.7 log10 CFUs, respectively.
Cresomycin (CRM) displaced 50% of bound radiolabeled erythromycin from immobilized E. coli ribosomes IC50 of ≤8.2 nM.
Cresomycin (CRM) exhibits in vitro and in vivo efficacy against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
| M.Wt | 498.68 | |
| Formula | C25H42N2O6S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Kelvin J Y Wu, et al. Science. 2024 Feb 16;383(6684):721-726.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
